Details for Patent: 9,649,364

Which drugs does patent 9,649,364 protect, and when does it expire?

Patent 9,649,364 protects GVOKE HYPOPEN and GVOKE PFS and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 9,649,364

Title:	Methods for producing stable therapeutic formulations in aprotic polar solvents
Abstract:	Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Inventor(s):	Prestrelski; Steven (San Diego, CA), Sandoval; Michael (Austin, TX), Donovan; Martin (Austin, TX)
Assignee:	XERIS PHARMACEUTICALS, INC. (Austin, TX)
Application Number:	15/136,650
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 9,649,364

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Xeris	GVOKE HYPOPEN	glucagon	SOLUTION;SUBCUTANEOUS	212097-003	Sep 10, 2019		RX	Yes	Yes			Y			TREATMENT OF SEVERE HYPOGLYCEMIA
Xeris	GVOKE HYPOPEN	glucagon	SOLUTION;SUBCUTANEOUS	212097-004	Sep 10, 2019		RX	Yes	Yes			Y			TREATMENT OF SEVERE HYPOGLYCEMIA
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No			Y			TREATMENT OF SEVERE HYPOGLYCEMIA
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes			Y			TREATMENT OF SEVERE HYPOGLYCEMIA

International Family Members for US Patent 9,649,364

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016326749
Brazil	112018005800
Canada	2999404
Canada	3204984
China	108135980
China	115531523
Eurasian Patent Organization	201890704